Key result
Multiple novel antivirals show preclinical promise against EV-D68 and rhinovirus, but none are approved.
Why the study?
Enterovirus-D68 and rhinoviruses cause significant respiratory illnesses in children, but no specific antiviral treatments are currently approved.
Answers are grounded in this paper and cite their sources.
Emerging therapeutic candidates targeting viral and host factors offer potential avenues for the future treatment of EV-D68 and rhinovirus infections.
BACKGROUND/OBJECTIVES: Enterovirus-D68 (EV-D68) and rhinoviruses are major contributors to respiratory illnesses in children, presenting a spectrum of clinical manifestations ranging from asymptomatic cases to severe lower respiratory tract infections. No specific antiviral treatments are currently approved for these viruses. METHOD: We conducted a comprehensive literature review of antiviral agents investigated for EV-D68 and rhinovirus infections. RESULTS: Several antiviral candidates are under investigation, each targeting distinct stages of the viral replicative cycle. Capsid-binding agents and monoclonal antibodies prevent viral attachment by blocking receptor-virus interactions. Inhibitors of viral replication proteins disrupt polyprotein processing and replication organelle biogenesis by targeting non-structural viral proteins. Host factor inhibitors impair viral attachment, replication organelle formation, or RNA replication by interfering with critical host pathways. CONCLUSIONS: While no specific antivirals are yet approved for EV-D68 and rhinovirus infections, emerging therapeutic candidates offer potential avenues for treatment. Continued preclinical and clinical investigation will be essential to validate these approaches and expand the available options for affected patients.
No takes yet. Share an insight, caveat, or question.
Rahajamanana et al. (2025) conducted a review in Enterovirus-D68 and Rhinovirus Respiratory Infections. Antiviral agents was evaluated. Several antiviral candidates targeting distinct stages of the viral replicative cycle are under investigation for EV-D68 and rhinovirus infections, though none are currently approved.
Synapse has enriched 10 related papers. Consider them for comparative context: